GPRC5D and Miyoshi myopathy: By targeting B cell maturation antigen (TNFRSF17; BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D), the prevention of BCMA escape-mediated relapse in MM models can be achieved [192].